As world’s cancer research community prepares to gather at the ASCO Annual Meeting, catch up with our recent studies presented earlier this year at AACR: https://t.co/2qLPwBq8Xp #precisiononcology #MachineLearning #techbio #FromCosmologyToOncology

Listen to our CEO Matt Foster discuss origins of Concr and how we work with partners to improve drug development to realise the promise of #PrecisionOncology in this episode of AI for Pharma Growth: https://t.co/hkMdoGrOxU #AI #MachineLearning #TechBio #FromCosmologyToOncology

#LSXWorld Congress in only 2 days away! You’re invited to our showcase on 3rd May at 14.30 at the newly-established techbio stage, to find out more about our current work and plans for the future. https://t.co/z9OME1oAIt #techbio #precisiononcology #fromcosmologytooncology

To access the story and learn more about VISION: https://t.co/OkP72EfRWy #SaMD #Genomics #ClinicalTrials #BreastCancer #PrecisionOncology #FromCosmologyToOncology

It is designed to validate Concr modelling to predict drug responses and patient survival for women with early #TNBC by merging clinical information with genomic data, identifying which drugs will work and which won’t, before the patient has started treatment.

Dr Uzma Asghar, who was recently profiled by @NHS_CEP outlining her experience as an NHS Clinical Entrepreneur explained the project at the forefront of Concr’s clinical validation efforts: the VISION study.

Having an #NHS medical oncologist as a Co-Founder and CSO doesn’t just mean that our predictions are clinically meaningful; it also ensures that Concr technology addresses unmet clinical needs, to the highest standards.

To read the article: https://t.co/AHVad4mnXh #TechBio #Biomarkers #CancerResearch #PrecisionOncology #FromCosmologyToOncology

In this piece, they explore how #biomarkers have already revolutionised the current clinical landscape, and what more needs to be done, in order to match more #cancer patients with safer, more effective and affordable therapies.

According to Concr’s translational medicine experts Uzma Asghar, Andrew Biankin and Philip Beer, recent advancements in #ML and #AI are set to make risky and costly drug development methods substantially more efficient and effective through #PrecisionDiagnostics.

Biomarkers hold the key to unlocking the links between intricate biological processes and clinical outcomes. For biomarkers to pave the way for reliable and accessible #PersonalisedMedicine, particularly in #cancer, they must be accurate, informative and cost-effective.

For more information about the Concr presentation and posters: https://t.co/MTNRly2OkB #TechBio #Cancer #MachineLearning #TranslationalOncology #FromCosmologyToOncology

Join Dr Matthew Griffiths and Dr Uzma Asghar in the poster hall (Section 33, Board Numbers 7 and 12) from 1:30 PM to learn about how Concr technology can differentiate tumours from other cell types from H&E slides, and identify tissue of origin from somatic mutation features.

If you're at #AACR23 today, then make sure to listen to Dr Aidan Kubeyev present on the results of the latest application of Concr’s prognostic #MachineLearning models on early #BreastCancer.

Find us at the TechBio Showcase on May 3rd at 2:30 PM or get in touch to book a 1:1 today! To find out more about Concr at LSX World Congress 2023: https://t.co/z9OME1p8y1 #TechBio #LSXWorld #PrecisionMedicine #FromCosmologyToOncology

Concr will be attending the 9th #LSXWorld Congress in London next month. Our Head of Strategy, Dr Irina Babina, will join the representatives of leading #biotech, #medtech and #healthtech companies to discuss the future of healthcare and life sciences innovation.

For more information about Concr at #AACR23: https://t.co/2HEKw8vS1B #TechBio #Cancer #MachineLearning #TranslationalOncology #FromCosmologyToOncology

Only three days left before #AACR23! With two posters and an oral presentation, there will be much to talk about! Come find us presenting on Tuesday 18th, or get in touch now to lock in a meeting with the Concr delegation: https://t.co/JGt8AH3tn9

The same statistical methodologies are at the heart of Concr’s algorithms aimed at unearthing #biomarkers of response to cancer treatments. To learn more about how Concr utilises this approach to make sense of disparate #oncology data: https://t.co/AyCWCcgW3D #TechBio

What do ultramassive #BlackHoles and #Cancer have in common? They are “elusive, and their origins are unclear”. Additionally, both are studied by our Durham University collaborator, @JwNightingale22, who applied a technique called #GravitationalLensing to the discovery.